Letter by Zhao and Schooling Regarding Article, “Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the recent study by Bano et al,1 which shows that thyroid function, indicated by thyroid-stimulating hormone, free thyroxine, and thyroid peroxidase antibodies, is associated with higher risk of atherosclerosis throughout its spectrum, from subclinical atherosclerosis, incident atherosclerotic cardiovascular events to cardiovascular mortality. This novel study could indicate a role of thyroid function in ischemic heart disease (IHD). However, these observed associations have not been corroborated by a randomized controlled trial of exogenous dextrothyroxine in secondary prevention of IHD2 and an MR (Mendelian randomization) study of prevalent IHD.3 Both study designs take advantage of randomization, of the treatment for randomized controlled trial, and of the random assortment …